OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Journal is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Toxicities From Antibody-Drug Conjugates	78
Social Drivers of Cancer Risk and Outcomes Among African American Men	44
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer	35
PET Imaging of Metabolism, Perfusion, and Hypoxia	23
Individualizing Therapy for Malignant Gliomas	20
Oncology Physician Workforce Diversity	20
Building a Bridge to Equity in Health and Health Care in Cancer Care	19
Health Care Policy and Disparities in Health	19
Stereotactic Body Radiation Therapy	17
Clinical Evidence Generation During a Pandemic	17
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer	17
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer	17
Melanoma—Modern Treatment for Metastatic Melanoma	15
Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies	14
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia	13
The Principles and Practice of PARP Inhibitor Therapy	13
c-Met Signaling as a Therapeutic Target in Head and Neck Cancer	13
Prostate Cancer, Race, and Health Disparity	12
Evaluation of the Prognostic Role of Liver Metastases on Patient Outcomes	12
Nonoperative Management for Rectal Cancer	12
Aurora Kinases as Therapeutic Targets in Head and Neck Cancer	11
Clinical Targeting of Altered Metabolism in High-Grade Glioma	11
Germline Predisposition to Myelodysplastic Syndromes	11
Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy	11
Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma	11

Diversity in Cancer Care	10
Metastatic Melanoma Treatment in Special Populations	10
Primary Prevention of Cancer	10
Antibody Drug Conjugates in Multiple Myeloma	9
Advanced Imaging and Computational Techniques for the Diagnostic and Prognostic Assessment of Malignant Gliomas	9
Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes	9
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia	9
Current State of Neoadjuvant Therapy for Locally Advanced Rectal Cancer	8
Overlooked and Damaging Impact of Structural Racism and Implicit Bias on US Health Care	8
Are We Witnessing a Paradigm Shift in the Treatment of Acute Myeloid Leukemia?	8
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer	8
Rectal Cancer—The Only Constant Is Change	8
DNA Damage Repair Inhibitors—Combination Therapies	8
Menopausal Hormone Therapy and Breast Cancer	7
The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance	7
Advances in Stereotactic Body Radiation Therapy for Lung Cancer	7
New Metabolomic Insights Into Cancer	7
Supportive Care for Patients With Myelodysplastic Syndromes	7
Overview of the Management of Higher-Risk Myelodysplastic Syndromes	7
Updates in the Management of Uveal Melanoma	7
Effective Personalization of Stereotactic Radiosurgery for Brain Metastases in the Modern Era	7
Evolving Landscape of Antibody Drug Conjugates in Lymphoma	6
Telemedicine and cancer care: Barriers and strategies to optimize delivery: Erratum	6
Telehealth and Technology	6
Role of the Microbiome in Immunotherapy of Melanoma	6
Neurosurgical Advances for Malignant Gliomas	6
PI3K Inhibition for Squamous Cell Head and Neck Carcinoma	6
Introduction	6
Impact of Precision Medicine in Oncology	6
Discovery of Natural Products for Cancer Prevention	6
Evolution of Therapy for Older Patients With Acute Myeloid Leukemia	6
Hormone Replacement Therapy After Breast Cancer	6
The Current Role of Human Papillomavirus Circulating Tumor DNA in Oropharynx Cancer	6
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease	6
Short- and Long-term Repercussions of Vancomycin on Immune Surveillance and the Efficacy of Antitumor Treatments	6
How Far We’ve Come	6